New study shows outstanding data integrity when transitioning from Progeny to CancerIQ
CHICAGO – February 25, 2025 –– CancerIQ and Fred Hutchinson Cancer Center migrated 13,000 patient records from Progeny’s commercial pedigree tool to CancerIQ’s precision prevention platform with remarkable data integrity, according to a new study in the peer-reviewed journal Genetics in Medicine.
The study, titled "Lessons Learned in Migrating from One Commercial Genetics Clinical Decision-Making Tool to Another," was led by the genetics team at Fred Hutch. It demonstrates how careful planning and collaboration can enable institutions undergoing similar transitions to maintain continuity of care and preserve data integrity while shifting their genetic risk assessment tools.
“Going from a legacy Progeny database to CancerIQ, we weren’t sure we would be able to transfer years of precious family history data safely and accurately, because there aren’t many research reports on data integrity after large health care data transfers,” said Marianne Dubard-Gault, MD, MS, principal investigator for this quality improvement study and a leading expert in cancer genetics. “We hope this publication gives others the confidence to switch to a newer, more advanced solution without worrying about losing their legacy family history data.”
By assessing 500 randomly selected charts after the migration, the team found a 92.2% concordance rate between the data in Progeny and CancerIQ. The discrepancies between datasets were attributed to inconsistencies in free-text fields and legacy data from before 2017. Recommendations were made to standardize data entry practices for future transitions.
“For decades, Progeny was the go-to tool for pedigree drawing and risk assessment in genetics programs. But with changes in ownership and the rise of more integrated technologies like CancerIQ, many programs—some with thousands of legacy patients—are making the switch.,” said Feyi Ayodele, founder and CEO, CancerIQ. “Through our work with sophisticated programs like Fred Hutch, we’ve advanced our data migration infrastructure to make the transition even faster and more seamless than ever.”
To access the full study, visit Genetics in Medicine’s website.
About CancerIQ
CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations. Learn more at canceriq.com and follow CancerIQ on LinkedIn.
Contact: Malvina Kefalas, CancerIQ, 516-503-8610, mkefalas@canceriq.com